BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for BV Karanam

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
42
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.EBI
Merck Research Laboratories
6
Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety.EBI
Merck Research Laboratories
21
Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid Moiety.EBI
Merck Research Laboratories
43
Imidazopyridines: a novel class of hNav1.7 channel blockers.EBI
Merck Research Laboratories
46
Discovery of imidazole carboxamides as potent and selective CCK1R agonists.EBI
Merck Research Laboratories
24
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.EBI
Merck Research Laboratories
38
2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.EBI
Merck Research Laboratories
29
Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity.EBI
Merck Research Laboratories
53
Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC).EBI
Merck
6
Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moiety.EBI
Merck
23
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.EBI
Merck Research Laboratories